Clinical trial NCT04632329: Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma
Official title: Negative Pressure Applied by the Equinox Mercury™ Multi-Pressure Dial to Lower and Modulate Intraocular Pressure in Subjects With Severe Open Angle Glaucoma (The Ranger Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma, Open-Angle
Lead sponsor: Equinox
Sponsor class: INDUSTRY
First posted: 2020-11-17
Enrollment: 64
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This is a prospective, non-significant risk, controlled, randomized, multi-center, masked, feasibility study to evaluate the safety and IOP-lowering effectiveness of negative pressure application (via the Mercury MPD) for lowering and titrating intraocular pressure (IOP) in severe open-angle glaucoma (OAG) patients. The study will be conducted at approximately three investigational sites in the United States. Between 60 and 100 subjects will be randomized to treatment. Treatment eyes will be administered two levels of negative pressure, calculated based on 50% and 75% of baseline IOP (as measured by pneumatonometry). One eye of each eligible subject will be randomized to receive negative pressure application with the MPD device; the contralateral eye will be used as a control and will be examined but will not undergo application of negative pressure. Subjects will be treated at each of the negative pressure levels for one hour. All study procedures will be conducted at one visit, and the subject will exit the study at the conclusion of the visit.


Eligibility criteria: Inclusion Criteria:

1. Male or female subjects ≥ 22 years of age at the time of signing the informed consent
2. Subjects willing to sign the informed consent and capable of committing to the study assessments
3. Subjects with orbital anatomy that permits a proper seal in both eyes when goggles are placed over eyes and can obtain IOP measurements with Excursion goggles in place
4. Subjects with a diagnosis of severe open-angle glaucoma (OAG definition is inclusive of primary open angle glaucoma, normal tension glaucoma, pseudoexfoliative glaucoma, and pigmentary glaucoma) in at least one eye, defined by glaucomatous optic disc or RNFL abnormalities AND visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield as tested with standard automated perimetry (the diagnosis of the contralateral eye may include suspected OAG\< as well as mild/moderate/severe OAG)
5. Subjects with treatment regimens including current ocular hypotensive medications, prior non-incisional surgical procedures (e.g. MIGS and SLT), or any combination of the two
6. Subjects who are literate, able to speak English or Spanish, and able to understand and follow study instructions

Exclusion Criteria:

1. Subjects with a history of allergy to primary study device material (i.e., silicone and latex)
2. Subjects with a history of any ocular disorder or condition (e.g., corneal transplant) in either eye that would likely interfere with the interpretation of the study results or compromise subject safety
3. Subjects with a history of retinal tear/detachment, wet macular degeneration, diabetic macular edema, or proliferative diabetic retinopathy
4. Subjects with active conjunctival chemosis or anterior uveitis
5. Subjects with a Van Herick grade of 2 or less.
6. Subjects with a history of prior incisional filtering (i.e. trabeculectomy) or tube/shunt glaucoma surgery in either eye
7. Subjects with best corrected visual acuity of 20/200 or worse in either eye due to glaucoma
8. Subjects who do not wish to or cannot comply with study procedures

Primary outcomes:
measure: IOP* reduction of ≥ 20% with 50% Negative Pressure for the treatment group vs. the control group
timeFrame: Day 1
measure: Mean IOP*reduction with 50% Negative Pressure for the treatment group vs. the control group
timeFrame: Day 1
Secondary outcomes:
measure: IOP* reduction of ≥ 25% with 75% Negative Pressure for the treatment group vs. the control group
timeFrame: Day 1
measure: Mean IOP*reduction with 75% Negative Pressure for the treatment group vs. the control group
timeFrame: Day 1
Other outcomes:
measure: Adverse Biomicroscopic Slit Lamp Findings
timeFrame: Day 1
measure: Rate of ocular/periocular adverse events (% by adverse event)
timeFrame: Day 1
measure: Corrected Distance Visual Acuity
timeFrame: Day 1
Locations:
city: Chicago
country: United States
facility: Illinois College of Optometry
state: Illinois
city: Sioux Falls
country: United States
facility: Vance Thompson Vision
state: South Dakota
city: San Antonio
country: United States
facility: R and R Eye Research, LLC
state: Texas
Study officials:
affiliation: New York Eye Surgery Center
name: Nate Radliffe, MD
role: STUDY_DIRECTOR
References: